Our Science – Fine Website

Howard A. Fine, M.D.

Neuro Oncology Branch Branch Chief Bloch Building, #82, Room 235 9030 Old Georgetown Road Bethesda, MD 20892 Phone:   301-402-6383 Fax:   301-480-2246 E-Mail:   hfine@mail.nih.gov Link: Other Homepage

Biography

Dr. Fine is currently chief of the Neuro-Oncology Branch at NCI's Center for Cancer Research, and of the National Institute of Neurologic Disorders and Stroke. He received his B.A. from the University of Pennsylvania, Philadelphia, and his M.D. from Mount Sinai School of Medicine, New York. Dr. Fine completed both his internship and his residency in internal medicine at the Hospital of The University of Pennsylvania. Three years later he completed his fellowship in medical oncology at Harvard Medical School's Dana-Farber Cancer Institute, Boston, MA. Before joining the NIH in 2000, Dr. Fine was both director of the Neuro-Oncology Disease Center at the Dana-Farber Cancer Institute, and of the Neuro-Oncology Program at the Harvard Cancer Center. The NCI senior investigator serves on several committees, including the Brain Tumor Program Review Group and the American Joint Committee on Cancer. Dr. Fine also serves on the editorial boards of several journals, including the Journal of Clinical Oncology, Neuro-Oncology, and The Oncologist. He has received several distinguished awards, including the Dana-Farber Harvard Cancer Center's Clinical Investigator Award in 1999, the Emil Frei III Clinical Investigator Award in 1993, and the Brain Tumor Society Research Award in 1992. His research interests include tumor angiogenesis, therapeutic gene transfer, and neural stem cell biology.

Research

View Dr. Fine's Current Clinical Trials

Developmental Therapeutics for Improved Treatment of Brain Tumors

The aim of the Neuro-Oncology Branch (NOB) is to develop an integrated clinical, translational, and basic research program that will engage the strengths and resources of both the NCI and the National Institute of Neurological Disorder and Stroke (NINDS) for the purpose of developing novel experimental therapeutics for children and adults with tumors of the central nervous system. Toward this end, the NOB has a growing laboratory effort devoted to developing new strategies for utilizing genetic vectors to explore basic biologic questions and develop novel therapeutic approaches that can be brought into the clinic. In addition, one of the major goals of the Neuro-Oncology Branch will be to closely align its efforts with the NIH-sponsored extramural effort in brain tumor basic and clinical research. In particular, it is the intention of the branch to set up close working collaborations with other NCI-sponsored collaborative clinical trials groups that have an interest in brain tumors for the purpose of synergizing the strengths of these groups (i.e., large patients accrual, outstanding data management) with some of the unique capabilities of the NIH intramural program (i.e., capability of doing highly novel, technically demanding, and expensive pilot trials). Through this alliance of basic and applied science, closely linked to individuals capable of conducting solid clinical investigation, a new generation of therapeutic breakthroughs will be realized.

We have collaborated with Edward Oldfield, NIH.

This page was last updated on 7/29/2008.